Kategori: Nyheder

"The Present", dokumentarfilm med Dimitri Poffé, er nu tilgængelig på Youtube

Dimitri Poffé is an already known member of the HD Community. After testing positive for Huntington’s Disease, Dimitri embraced a bicycle journey through South America. In this project, called Explore […]

PTC Therapeutics indgår en global licens- og samarbejdsaftale med Novartis om PTC518 Huntingtons sygdomsprogram

December 2, 2024 – PTC to receive $1.0B in cash at closing –– PTC is eligible to receive up to $1.9B in development, regulatory and sales milestones –– PTC to share profits in the U.S. and […]

Sage Therapeutics indstiller udviklingen af dalzanemdor i HS

The Phase 2 DIMENSION Study did not meet its primary endpoint Dalzanemdor was generally well-tolerated; no new safety signals were observed Based on these data, the Company does not plan […]

Partnerskabets magt. Schweiz og Kina er et eksempel til efterfølgelse.

In this video, Professor Jean-Marc Burgunder, head of the Huntington’s Disease (HD) centre in Bern Switzerland, and Xi Cao, President of the Chinese HD Association talk about the benefits of […]

Livable Lives - en ny bog, der fremhæver historier fra mennesker, der er påvirket af HS rundt om i verden

PRESS RELEASE – October 25, 2024, Moscow, Idaho, USAWe are pleased to announce the launch of a new book about Huntington’s disease (HD) called, Livable Lives: Conversations with the Huntington’s […]

LoQus23 Therapeutics annoncerer finansiering på 35 millioner pund for at fremme et nyt lægemiddel, der har til formål at hæmme somatisk ekspansion i Huntingtons sygdom

Cambridge, UK, 2 October 2024 – LoQus23 Therapeutics Ltd (“LoQus23”), a private biotechnology company investigating small molecule drugs that could stop DNA instability and slow neurodegeneration in Huntington’s Disease, myotonic dystrophy […]

FDA giver Fast Track-status til PTC518 Huntingtons sygdomsprogram

PTC518 is an oral medication that reduces the production of the mutated Huntingtin protein that causes disease progression.   Programs with Fast Track designation can benefit from early interactions with the FDA, and may be […]

Prilenias pridopidin til Huntingtons sygdom godkendt til gennemgang af europæisk markedsføringstilladelse

Prilenia, a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative diseases and neurodevelopmental disorders, has filed a European Marketing […]

IROS, Prilenia og International Huntington's Disease Association samarbejder om det første forsøg med Huntingtons sygdom (HS) nogensinde i MENA-regionen

Abu Dhabi, UAE; June 19, 2024: IROS, an Abu Dhabi-based contract research organization (part of the M42 group), has partnered with Prilenia Therapeutics, a clinical-stage biotech company, and the International […]

uniQure annoncerer en positiv opdatering af foreløbige data, der viser en opbremsning af sygdomsudviklingen i fase I/II-forsøg med AMT-130 til HS

"Vi er meget tilfredse med disse nye data, der viser en statistisk signifikant, dosisafhængig opbremsning af udviklingen af Huntingtons sygdom og en sænkning af NfL i CSF efter 24 måneder," [...].